Carisma Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 24.64 million compared to USD 11.31 million a year ago. Basic loss per share from continuing operations was USD 1.93 compared to USD 5.49 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 USD | 0.00% | +0.61% | -44.03% |
Apr. 11 | BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target | MT |
Apr. 02 | HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.03% | 68.13M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CARM Stock
- News Carisma Therapeutics, Inc.
- Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023